DE69434046D1 - Nicht-antigene verzweigte Polymerconjugate - Google Patents

Nicht-antigene verzweigte Polymerconjugate

Info

Publication number
DE69434046D1
DE69434046D1 DE69434046T DE69434046T DE69434046D1 DE 69434046 D1 DE69434046 D1 DE 69434046D1 DE 69434046 T DE69434046 T DE 69434046T DE 69434046 T DE69434046 T DE 69434046T DE 69434046 D1 DE69434046 D1 DE 69434046D1
Authority
DE
Germany
Prior art keywords
branched polymer
polymer conjugates
antigenic
antigenic branched
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69434046T
Other languages
English (en)
Other versions
DE69434046T2 (de
Inventor
Richard B Greenwald
Anthony Martinez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzon Pharmaceuticals Inc
Original Assignee
Enzon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22503911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69434046(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
US case filed in Alabama Northern District Court litigation https://portal.unifiedpatents.com/litigation/Alabama%20Northern%20District%20Court/case/5%3A00-cv-01310 Source: District Court Jurisdiction: Alabama Northern District Court "Unified Patents Litigation Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Enzon Inc filed Critical Enzon Inc
Application granted granted Critical
Publication of DE69434046D1 publication Critical patent/DE69434046D1/de
Publication of DE69434046T2 publication Critical patent/DE69434046T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C08G65/3322—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof acyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Peptides Or Proteins (AREA)
  • Polyamides (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69434046T 1993-10-27 1994-10-24 Nicht-antigene verzweigte Polymerconjugate Expired - Lifetime DE69434046T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/143,403 US5643575A (en) 1993-10-27 1993-10-27 Non-antigenic branched polymer conjugates
US143403 1993-10-27

Publications (2)

Publication Number Publication Date
DE69434046D1 true DE69434046D1 (de) 2004-11-04
DE69434046T2 DE69434046T2 (de) 2005-10-06

Family

ID=22503911

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69434046T Expired - Lifetime DE69434046T2 (de) 1993-10-27 1994-10-24 Nicht-antigene verzweigte Polymerconjugate
DE69427045T Expired - Lifetime DE69427045T2 (de) 1993-10-27 1994-10-24 Nicht-antigene verzweigte polymer-konjugate

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69427045T Expired - Lifetime DE69427045T2 (de) 1993-10-27 1994-10-24 Nicht-antigene verzweigte polymer-konjugate

Country Status (8)

Country Link
US (1) US5643575A (de)
EP (2) EP1055685B1 (de)
JP (1) JP3626494B2 (de)
AU (1) AU8090294A (de)
CA (1) CA2174325C (de)
DE (2) DE69434046T2 (de)
DK (2) DK0788515T3 (de)
WO (1) WO1995011924A1 (de)

Families Citing this family (560)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030203976A1 (en) 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
DK0797988T3 (da) * 1993-07-19 2009-05-11 Univ British Columbia Anti-angiogene præparater og fremgangsmåder til anvendelse deraf
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
ZA963530B (en) * 1995-05-05 1996-11-05 Hoffmann La Roche Recombinant obese (ob) proteins
EP0741187A2 (de) * 1995-05-05 1996-11-06 F. Hoffmann-La Roche Ag Rekombinante Obesitäts-(OB)-Proteine
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
JP4193917B2 (ja) * 1995-12-18 2008-12-10 アンジオデバイス インターナショナル ゲーエムベーハー 架橋ポリマー組成物およびその使用方法
US6458889B1 (en) 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US7883693B2 (en) 1995-12-18 2011-02-08 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
US6833408B2 (en) 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
NZ332234A (en) * 1996-03-12 2000-06-23 Pg Txl Company Lp Water soluble paclitaxel prodrugs formed by conjugating paclitaxel or docetaxel with a polyglutamic acid polymer and use for treating cancer
US7357927B2 (en) * 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) * 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
CA2262994A1 (en) * 1996-08-02 1998-02-12 Ortho-Mcneil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US7122636B1 (en) * 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
EP0968291B1 (de) 1997-02-21 2004-01-28 Genentech, Inc. Antikörperfragment-polymerkonjugate
NZ508381A (en) * 1997-03-17 2002-09-27 Human Genome Sciences Inc Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
US20050233958A1 (en) * 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
US20080248046A1 (en) * 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
US20040136951A1 (en) * 1997-03-17 2004-07-15 Human Genome Sciences, Inc. Death domain containing receptor 5
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US5900402A (en) * 1997-05-29 1999-05-04 Enzon, Inc. Method of reducing side effects associated with administration of oxygen-carrying proteins
US6284246B1 (en) * 1997-07-30 2001-09-04 The Procter & Gamble Co. Modified polypeptides with high activity and reduced allergenicity
CN1276730A (zh) * 1997-09-18 2000-12-13 霍夫曼-拉罗奇有限公司 α－干扰素和金刚胺用于治疗慢性丙型肝炎的应用
EP1040151A4 (de) * 1997-12-12 2003-05-21 Macromed Inc Heterofunktionelle sternförmige polyethylenglykole zur proteinmodifizierung
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
JP4465109B2 (ja) 1997-12-17 2010-05-19 エンゾン ファーマシューティカルズ，インコーポレーテッド アミノ及びヒドロキシル含有生物活性剤のポリマープロドラッグ
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US7005504B2 (en) * 1998-01-22 2006-02-28 Genentech, Inc. Antibody fragment-peg conjugates
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US6066673A (en) * 1998-03-12 2000-05-23 The Procter & Gamble Company Enzyme inhibitors
US6942859B2 (en) 1998-03-13 2005-09-13 University Of Southern California Red blood cells covalently bound with polymers
US6312685B1 (en) 1998-03-13 2001-11-06 Timothy C. Fisher Red blood cells covalently bound with two different polyethylene glycol derivatives
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6251382B1 (en) 1998-04-17 2001-06-26 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
IL139786A0 (en) * 1998-06-08 2002-02-10 Hoffmann La Roche Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
US6214330B1 (en) 1998-07-13 2001-04-10 Enzon, Inc. Coumarin and related aromatic-based polymeric prodrugs
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US20060188971A1 (en) * 1998-08-06 2006-08-24 Duke University Urate oxidase
ES2245114T3 (es) 1998-08-06 2005-12-16 Mountain View Pharmaceuticals, Inc. Conjugados de peg-oxidasa de urato y su uso.
CN1322243A (zh) 1998-08-06 2001-11-14 杜克大学 尿酸氧化酶
ES2265693T3 (es) * 1998-10-16 2007-02-16 Biogen Idec Ma Inc. Proteinas de fusion con interferon-beta y usos.
ES2630278T3 (es) 1998-10-16 2017-08-21 Biogen Ma Inc. Conjugados poliméricos de interferón beta-1a y usos de los mismos
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
AU768027B2 (en) * 1999-02-24 2003-11-27 Uab Research Foundation, The Taxane derivatives for targeted therapy of cancer
CA2363779A1 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6852696B2 (en) 1999-03-26 2005-02-08 The University Of Texas System Inhibitors of glycosaminoglycans
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
JP2003508564A (ja) * 1999-08-27 2003-03-04 コヒージョン テクノロジーズ， インコーポレイテッド 高強度の医療用シーラントとして使用するための相互侵入ポリマー網目構造を形成する組成物
CN1111166C (zh) * 1999-09-10 2003-06-11 云南汉德生物技术有限公司 水溶性三尖杉磷碱聚氨基酸酯或其盐,含它们的药物组合物及其医药用途
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6376470B1 (en) 1999-09-23 2002-04-23 Enzon, Inc. Polymer conjugates of ara-C and ara-C derivatives
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
JP4593048B2 (ja) * 1999-12-24 2010-12-08 協和発酵キリン株式会社 分岐型ポリアルキレングリコール類
ES2327606T3 (es) 2000-01-10 2009-11-02 Maxygen Holdings Ltd Conjugados de g-csf.
DE60138364D1 (de) 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
US6777387B2 (en) 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
US6756037B2 (en) 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
EP1280849B1 (de) * 2000-04-04 2006-08-23 Bioartificial Gel Technologies Inc. Verfahren zur herstellung proteinhaltigen hydrogelen
EP1276849A4 (de) 2000-04-12 2004-06-09 Human Genome Sciences Inc Albumin fusionsproteine
WO2001087329A1 (en) 2000-05-15 2001-11-22 F. Hoffmann-La Roche Ag Liquid pharmaceutical composition containing an erythropoietin derivate
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
AU2001268228A1 (en) 2000-06-08 2001-12-17 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
WO2001096528A2 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
PT2275449T (pt) * 2000-06-16 2016-12-27 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
KR20030032977A (ko) * 2000-07-12 2003-04-26 그리폰 테라퓨틱스, 인코포레이티드 키모카인 수용체 조절제, 제조 및 사용
KR100396983B1 (ko) * 2000-07-29 2003-09-02 이강춘 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
WO2002016412A2 (en) 2000-08-18 2002-02-28 Dyax Corp. Binding polypeptides for b lymphocyte stimulator protein (blys)
US20030091565A1 (en) * 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
RU2003109746A (ru) * 2000-09-08 2005-01-27 Грифон Терапьютикс, Инк. (Us) Синтетические белки, стимулирующие эритропоэз
US7052686B2 (en) * 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
US20020065397A1 (en) 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
AU2001290312A1 (en) 2000-10-16 2002-04-29 Chugai Seiyaku Kabushiki Kaisha Peg-modified erythropoietin
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7053150B2 (en) 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
US20030054015A1 (en) * 2000-12-25 2003-03-20 Shinichiro Haze Sympathetic-activating perfume composition
CA2436623C (en) * 2001-01-30 2011-08-02 Kyowa Hakko Kogyo Co., Ltd. Branched polyalkylene glycols
ES2284858T3 (es) 2001-02-02 2007-11-16 Ortho-Mcneil Pharmaceutical, Inc. Tratamiento de disfuncion neurologica que comprende sulfamatos de fructopiranosa y eritropoyetina.
DK1362053T3 (da) * 2001-02-20 2008-03-10 Enzon Inc Terminalt forgrenede polymere linkere og polymere konjugater indeholdende disse
YU48703A (sh) 2001-02-27 2006-05-25 Maxygen Aps Novi interferonu beta-slični molekuli
AU2002258749A1 (en) * 2001-03-21 2002-10-08 The University Of Texas System Inhibitors of glycosaminoglycans
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
WO2002097033A2 (en) 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US20040077835A1 (en) * 2001-07-12 2004-04-22 Robin Offord Chemokine receptor modulators, production and use
WO2003018665A1 (en) * 2001-08-22 2003-03-06 Bioartificial Gel Technologies Inc. Process for the preparation of activated polyethylene glycols
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
EP2050460A1 (de) * 2001-09-24 2009-04-22 Imperial Innovations Limited PYY und dessen Agonisten zur Änderung des Fütterverhaltens
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
US7026440B2 (en) * 2001-11-07 2006-04-11 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
CA2468499A1 (en) * 2001-11-28 2003-06-05 Ortho-Mcneil Pharmaceutical, Inc. Erythropoietin dosing regimen for treating anemia
US20030180296A1 (en) * 2001-12-20 2003-09-25 Theodora Salcedo Antibodies that immunospecifically bind to trail receptors
EP2277889B1 (de) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusionsproteine von Albumin und Interferon beta
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
JP4733922B2 (ja) 2002-01-10 2011-07-27 インペリアル・イノベ−ションズ・リミテッド 摂食行動の修正
US7144978B2 (en) 2002-01-15 2006-12-05 Pan Asia Bio Co., Ltd. Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
AU2003218045A1 (en) * 2002-03-11 2003-09-29 Ortho Mcneil Pharmaceutical, Inc Methods for shp1 mediated neuroprotection
JP4272537B2 (ja) * 2002-03-13 2009-06-03 北京鍵▲凱▼科技有限公司 Ｙ型分鎖親水性ポリマー誘導体、それらの調製方法、前記誘導体および薬剤分子の結合生成物、ならびに前記結合生成物を含む医薬組成物
WO2003078461A1 (en) * 2002-03-20 2003-09-25 Biopolymed Inc. Preparation of g-csf stoichiometrically conjugated with biocompatible polymers at cystein residue
WO2003085093A2 (en) * 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
ITMI20020951A1 (it) * 2002-05-06 2003-11-06 Univ Degli Studi Trieste Derivati multifunzionali del polietilenglicole loro preparazione ed impiego
ATE518885T1 (de) * 2002-05-28 2011-08-15 Ucb Pharma Sa Peg-positionsisomer von einem antikorper gegen tnfalpha (cdp870)
DK1517710T3 (da) 2002-06-21 2011-07-18 Novo Nordisk Healthcare Ag Pegylerede faktor VII-glycoformer
DE60336555D1 (de) 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
US20060094643A1 (en) * 2002-07-03 2006-05-04 Yuri Svirkin Compositions of hyaluronic acid and methods of use
ES2601143T3 (es) 2002-07-19 2017-02-14 Omeros Corporation Copolímeros tribloque biodegradables, métodos de síntesis de los mismos, e hidrogeles y biomateriales preparados a partir de los mismos
US7122189B2 (en) * 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7413738B2 (en) * 2002-08-13 2008-08-19 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on biodegradable linkers
US7087229B2 (en) * 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
WO2004019860A2 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Formulations of modified antibodies and methods of making the same
AU2003265361A1 (en) * 2002-08-28 2004-03-19 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
TWI281864B (en) * 2002-11-20 2007-06-01 Pharmacia Corp N-terminally monopegylated human growth hormone conjugates and process for their preparation
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
TWI364295B (en) * 2002-12-26 2012-05-21 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
PL219741B1 (pl) * 2002-12-26 2015-07-31 Mountain View Pharmaceuticals Sposób zwiększania antyproliferacyjnego potencjału nieglikozylowanego interferonu-beta-1b in vitro, koniugat wytworzony tym sposobem i jego zastosowanie oraz kompozycja farmaceutyczna zawierająca koniugat i jej zastosowanie
WO2004060405A2 (en) * 2002-12-30 2004-07-22 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
WO2004061094A1 (en) 2002-12-30 2004-07-22 Gryphon Therapeutics, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
JP2006516548A (ja) * 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
CA2517145C (en) * 2003-03-05 2017-08-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
KR20060003862A (ko) 2003-03-14 2006-01-11 네오스 테크놀로지스, 인크. 수용성분기폴리머 및 그 접합체
WO2006127896A2 (en) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2004091517A2 (en) 2003-04-15 2004-10-28 Smithkline Beecham Corporation Conjugates comprising human il-18 and substitution mutants thereof
US7932364B2 (en) * 2003-05-09 2011-04-26 Novo Nordisk A/S Compositions and methods for the preparation of human growth hormone glycosylation mutants
WO2005016241A2 (en) 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
ES2725808T3 (es) * 2003-05-23 2019-09-27 Nektar Therapeutics Derivados de PEG que contienen dos cadenas de PEG
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
WO2005023294A2 (en) 2003-09-05 2005-03-17 The General Hospital Corporation Polyacetal drug conjugates as release system
EP1525890A1 (de) * 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophor Komplex
SG143252A1 (en) * 2003-10-09 2008-06-27 Ambrx Inc Polymer derivatives
CN102516386A (zh) 2003-10-10 2012-06-27 诺沃挪第克公司 Il-21衍生物
RS20060259A (en) 2003-10-14 2008-08-07 Intermune Inc., Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
EP2641611A3 (de) 2003-10-17 2013-12-18 Novo Nordisk A/S Kombinationstherapie
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
EP1694347B1 (de) * 2003-11-24 2013-11-20 BioGeneriX AG Glycopegyliertes Erythropoetin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
EP1694351A2 (de) * 2003-12-03 2006-08-30 Neose Technologies, Inc. Glycopegyliertes follikel-stimulierendes hormon
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
NZ594834A (en) * 2003-12-16 2013-03-28 Nektar Therapeutics Method of preparing PEGylated protein molecules
EP1696947B1 (de) 2003-12-19 2014-02-26 F.Hoffmann-La Roche Ag Verwendung von erythropoietin zur behandlung von störungen des eisen verteilung in chronische entzündliche darmerkrankungen
KR101439880B1 (ko) 2004-01-08 2014-09-12 라티오팜 게엠베하 펩티드의 오-결합형 글리코실화
AU2005211362B2 (en) 2004-02-02 2008-03-13 Ambrx, Inc. Modified human interferon polypeptides and their uses
AU2005319099B2 (en) * 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
BRPI0507026A (pt) 2004-02-09 2007-04-17 Human Genome Sciences Inc proteìnas de fusão de albumina
US6887952B1 (en) * 2004-02-12 2005-05-03 Biosite, Inc. N-aryl-carbamic acid ester-derived and valeric acid ester-derived cross-linkers and conjugates, and methods for their synthesis and use
US7351787B2 (en) 2004-03-05 2008-04-01 Bioartificial Gel Technologies, Inc. Process for the preparation of activated polyethylene glycols
US20050238628A1 (en) * 2004-04-08 2005-10-27 Blau Carl A Methods for treating cancer
BRPI0510477B1 (pt) 2004-04-28 2023-01-17 Angiotech Biomaterials Corporation Método para formar um gel e dispositivo para uso em aplicações médicas
US8562965B2 (en) 2004-05-03 2013-10-22 Nektar Therapeutics Polymer derivatives comprising an acetal or ketal branching point
CA2568952C (en) * 2004-06-18 2019-05-21 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
EP1771066A2 (de) 2004-07-13 2007-04-11 Neose Technologies, Inc. Remodellierung von verzweigtem peg und klykolysierung von glucagonähnlichem peptide-1 glp-1
CA2910494C (en) 2004-07-19 2018-10-23 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
MX2007000728A (es) * 2004-07-21 2007-03-15 Ambrx Inc Polipeptidos biosinteticos que utilizan amino acidos no naturalmente codificados.
US20090292110A1 (en) * 2004-07-23 2009-11-26 Defrees Shawn Enzymatic modification of glycopeptides
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
WO2006020580A2 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1794588A2 (de) * 2004-09-09 2007-06-13 Biosite Incorporated Verfahren und zusammensetzungen zur messung von hunde-bnp und verwendungen davon
US8268967B2 (en) 2004-09-10 2012-09-18 Novo Nordisk A/S Glycopegylated interferon α
US8303973B2 (en) 2004-09-17 2012-11-06 Angiotech Pharmaceuticals (Us), Inc. Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use
DE602005027862D1 (de) 2004-10-07 2011-06-16 Du Pont Polymer auf basis von polysaccharide für gewebekleber zur medizinischen verwendung
US8790632B2 (en) * 2004-10-07 2014-07-29 Actamax Surgical Materials, Llc Polymer-based tissue-adhesive form medical use
ES2572779T3 (es) 2004-10-29 2016-06-02 Ratiopharm Gmbh Remodelación y glucopegilación del Factor de Crecimiento de Fibroblastos (FGF)
NZ555386A (en) 2004-12-22 2011-01-28 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
JP5425398B2 (ja) 2004-12-22 2014-02-26 アンブレツクス・インコーポレイテツド 非天然アミノ酸及びポリペプチドを含む組成物、非天然アミノ酸及びポリペプチドに関連する方法並び非天然アミノ酸及びポリペプチドその使用
EP1836316A4 (de) 2004-12-22 2009-07-22 Ambrx Inc Verfahren zur expression und reinigung von rekombinantem menschlichem wachstumshormon
JP4990792B2 (ja) * 2004-12-22 2012-08-01 アンブレツクス・インコーポレイテツド アミノアシル−ｔＲＮＡシンテターゼの組成物およびこの使用
ES2449195T3 (es) 2005-01-10 2014-03-18 Ratiopharm Gmbh Factor estimulante de colonias de granulocitos glicopegilado
WO2006078813A2 (en) * 2005-01-21 2006-07-27 Biosite Incorporated Arginine analogs, and methods for their synthesis and use
US7365127B2 (en) * 2005-02-04 2008-04-29 Enzon Pharmaceuticals, Inc. Process for the preparation of polymer conjugates
EP1850858A2 (de) * 2005-02-10 2007-11-07 Emory University Polyethylenoxid-polymere mit entzündungshemmenden glycodendronen
EP1857462B9 (de) 2005-02-18 2013-02-13 Nof Corporation Polyoxyalkylenderivat
EP1854807A4 (de) * 2005-02-18 2009-04-01 Univ Tokushima Eine polyoxyalkylenkette enthaltendes lipidderivat und eine lipidfilmstruktur, die ein solches derivat enthält
JP2008534640A (ja) 2005-04-05 2008-08-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー タンパク質の機能部位またはエピトープの遮蔽方法
EP2386571B1 (de) 2005-04-08 2016-06-01 ratiopharm GmbH Zusammensetzungen und Verfahren zur Herstellung von Glycosylierungsmutanten eines Proteaseresistenten menschlichen Wachstumshormons
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
CN101194016B (zh) 2005-04-11 2012-09-05 萨文特医药公司 尿酸氧化酶的变体形式及其用途
US9534013B2 (en) * 2006-04-12 2017-01-03 Horizon Pharma Rheumatology Llc Purification of proteins with cationic surfactant
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
PT3321359T (pt) 2005-04-11 2021-03-11 Horizon Pharma Rheumatology Llc Formas variantes de urato-oxidase e a sua utilização
WO2006110776A2 (en) 2005-04-12 2006-10-19 Nektar Therapeutics Al, Corporation Polyethylene glycol cojugates of antimicrobial agents
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
JP2008545665A (ja) * 2005-05-23 2008-12-18 ユニベルシテ ドゥ ジュネーブ 高体温による処置のための注入可能な超常磁性ナノ粒子および高体温インプラントを形成するための使用
EP1888098A2 (de) 2005-05-25 2008-02-20 Neose Technologies, Inc. Glykopegylierte erythropoetin-formulierungen
ATE529442T1 (de) * 2005-06-03 2011-11-15 Ambrx Inc Verbesserte humane interferon-moleküle und ihre verwendungen
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
JP5335422B2 (ja) 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
EP2412744B1 (de) * 2005-07-18 2014-01-22 Nektar Therapeutics Verfahren zur Herstellung von verzweigten funktionalisierten Polymeren mithilfe von verzweigten Polyol-Kernen
KR100735784B1 (ko) * 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
CN103103238B (zh) 2005-08-18 2016-08-10 Ambrx公司 一种在细胞中制造在特定位置处具有所选氨基酸的抗体或抗体片段多肽的方法
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US8679536B2 (en) * 2005-08-24 2014-03-25 Actamax Surgical Materials, Llc Aldol-crosslinked polymeric hydrogel adhesives
US8679537B2 (en) * 2005-08-24 2014-03-25 Actamaz Surgical Materials, LLC Methods for sealing an orifice in tissue using an aldol-crosslinked polymeric hydrogel adhesive
US7601798B2 (en) * 2005-10-04 2009-10-13 Enzon Pharmaceuticals, Inc. Methods of preparing polymers having terminal amine groups using protected amine salts
KR20140077946A (ko) * 2005-10-13 2014-06-24 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
AU2006311568B2 (en) * 2005-11-08 2010-11-11 Ambrx, Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
EP1951890A4 (de) * 2005-11-16 2009-06-24 Ambrx Inc Verfahren und zusammensetzungen mit nichtnatürlichen aminosäuren
DK1968635T3 (en) * 2005-12-14 2014-12-15 Ambrx Inc Compositions and Methods of, and uses of non-natural amino acids and polypeptides
US7989554B2 (en) 2006-01-10 2011-08-02 Enzon Pharmaceuticals, Inc. Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
JP5528710B2 (ja) * 2006-02-28 2014-06-25 オリガシス コーポレイション アクリロイルオキシエチルホスホリルコリン含有ポリマー抱合体及びその製法
CA2645844C (en) 2006-03-13 2016-04-26 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
CN101062407A (zh) 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 促红细胞生成素在预防或治疗视网膜损伤中的用途
EP2395099A3 (de) 2006-05-02 2012-05-16 Allozyne, Inc. Aminosäuresubstituierte Moleküle
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
EP2213733A3 (de) 2006-05-24 2010-12-29 Novo Nordisk Health Care AG Analoge des Faktor IX mit verlängerter Halbwertszeit in vivo
EP2035016A2 (de) * 2006-06-09 2009-03-18 Enzon Pharmaceuticals, Inc. Indenoisochinolin-lösliche polymer-konjugate
AU2007275535B2 (en) * 2006-06-30 2012-08-16 Servier IP UK Limited Recombinant host for producing L-asparaginase II
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
EP2054437A2 (de) * 2006-08-07 2009-05-06 Teva Biopharmaceuticals USA, Inc. Albumin-insulin-fusionsproteine
EP2615108B1 (de) * 2006-09-08 2016-10-26 Ambrx, Inc. Modifiziertes humanes Plasmapolypeptid oder Fc-Gerüste und deren Verwendungen
DK2061878T3 (da) * 2006-09-08 2014-04-07 Ambrx Inc Hybridsuppressor-trna for hvirveldyrceller
MX2009002526A (es) * 2006-09-08 2009-04-16 Ambrx Inc Transcripcion de tarn supresor en celulas de vertebrados.
US8367065B2 (en) * 2006-09-15 2013-02-05 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
WO2008034124A2 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
US8110559B2 (en) * 2006-09-15 2012-02-07 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
NZ597098A (en) 2006-09-28 2013-05-31 Merck Sharp & Dohme Use of pegylated il-10 to treat cancer
EP2054521A4 (de) * 2006-10-03 2012-12-19 Novo Nordisk As Verfahren zur reinigung von polypeptid-konjugate
JP5457185B2 (ja) 2006-10-04 2014-04-02 ノヴォ ノルディスク アー／エス グリセロール連結のｐｅｇ化された糖および糖ペプチド
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
CN101168594B (zh) * 2006-10-24 2011-07-27 北京键凯科技有限公司 寡肽为骨架的聚乙二醇活性衍生物、其制备方法及与药物分子的结合物
PE20081140A1 (es) * 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
US8282959B2 (en) * 2006-11-27 2012-10-09 Actamax Surgical Materials, Llc Branched end reactants and polymeric hydrogel tissue adhesives therefrom
TWI428346B (zh) * 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
JP5340956B2 (ja) * 2006-12-20 2013-11-13 アーケマ・インコーポレイテッド ポリマーの封入および／または結合
WO2008083302A2 (en) * 2006-12-29 2008-07-10 Enzon Pharmaceuticals, Inc. Use of adenosine deaminase for treating pulmonary disease
WO2008089185A2 (en) * 2007-01-16 2008-07-24 Enzon Pharmaceuticals, Inc. Posaconazole polymer conjugates and methods of treatment using posaconazole and polymer conjugates thereof
CN101677588A (zh) * 2007-02-01 2010-03-24 加拿大国家研究委员会 亲脂性生物活性分子制剂
ATE554785T1 (de) 2007-03-30 2012-05-15 Ambrx Inc Modifizierte fgf-21 polypeptide und ihre verwendung
CA2682897C (en) 2007-04-03 2016-11-22 Biogenerix Ag Methods of treatment using glycopegylated g-csf
EP2147116B1 (de) * 2007-04-20 2016-03-02 Sigma-Tau Rare Disease Ltd Stabile rekombinante adenosin-deaminase
TWI486169B (zh) * 2007-04-20 2015-06-01 Sigma Tau Rare Diseases S A 酵素性抗癌療法
WO2008137471A2 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
MX2009012609A (es) 2007-05-22 2009-12-07 Amgen Inc Composiciones y metodos para producir proteinas de fusion bioactivas.
CN101778859B (zh) 2007-06-12 2014-03-26 诺和诺德公司 改良的用于生产核苷酸糖的方法
CA2693616A1 (en) * 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery system containing a multi-substituted aromatic moiety
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
US8088884B2 (en) * 2007-09-27 2012-01-03 Serina Therapeutics, Inc. Multi-armed forms of activated polyoxazoline and methods of synthesis thereof
MX2010003979A (es) 2007-10-16 2010-06-02 Biocon Ltd Composicion farmaceutica oralmente administrable y proceso para su preparacion.
EP2214731B1 (de) * 2007-11-14 2014-05-14 Actamax Surgical Materials LLC Auf oxidiertem kationischem polysaccharid basierendes polymergewebehaftmittel zur medizinischen verwendung
US8846095B2 (en) 2007-11-14 2014-09-30 Actamax Surgical Materials, Llc Dextran-based polymer tissue adhesive for medical use
EP2930182A1 (de) 2007-11-20 2015-10-14 Ambrx, Inc. Modifizierte insulinpolypeptide und deren verwendungen
US8101706B2 (en) 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
WO2009089542A2 (en) 2008-01-11 2009-07-16 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
EP2260102A1 (de) 2008-03-25 2010-12-15 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tumorbehandlung mittels herunterregelung von frizzled-4 und/oder frizzled-1
SG187427A1 (en) 2008-04-14 2013-02-28 Halozyme Inc Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
NZ588408A (en) 2008-04-16 2012-05-25 Biogen Idec Inc Method of isolating proteins using polyethylene glycol and zinc
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
EP2280739B1 (de) * 2008-06-03 2012-07-04 Actamax Surgical Materials LLC Gewebebeschichtung zur verhinderung unerwünschter gewebeverklebungen
AU2009268841B2 (en) 2008-07-08 2014-02-06 Board Of Regents, The University Of Texas System Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (STATS)
US8551136B2 (en) 2008-07-17 2013-10-08 Actamax Surgical Materials, Llc High swell, long-lived hydrogel sealant
US20100015231A1 (en) * 2008-07-17 2010-01-21 E.I. Du Pont De Nemours And Company Low swell, long-lived hydrogel sealant
US10138283B2 (en) 2008-07-23 2018-11-27 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
JP5639585B2 (ja) 2008-07-31 2014-12-10 ファーマエッセンティア コーポレイション ペプチド−ポリマー共役体
US8716446B2 (en) * 2008-08-25 2014-05-06 Biopolymed Inc. Biopolymer conjugates comprising an interleukin-11 analog
MX2011003196A (es) 2008-09-26 2011-04-27 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
CN102232085A (zh) 2008-09-26 2011-11-02 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
EP2356251A1 (de) 2008-11-07 2011-08-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Teneurin und krebs
US8466327B2 (en) 2008-11-19 2013-06-18 Actamax Surgical Materials, Llc Aldehyde-functionalized polyethers and method of making same
US9044529B2 (en) * 2008-11-19 2015-06-02 Actamax Surgical Materials, Llc Hydrogel tissue adhesive formed from aminated polysaccharide and aldehyde-functionalized multi-arm polyether
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
KR101546563B1 (ko) 2008-12-09 2015-08-28 할로자임, 아이엔씨 연장된 가용성 ｐｈ20 폴리펩티드 및 그의 용도
CN102307473A (zh) 2008-12-10 2012-01-04 摩萨纳医疗有限公司 可生物降解的生物相容性喜树碱-聚合物共轭物的药物制剂
HUE037936T2 (hu) 2008-12-17 2018-09-28 Merck Sharp & Dohme Mono- és di-pegil IL-10 elõállítása és alkalmazása
US20100160960A1 (en) * 2008-12-19 2010-06-24 E. I. Du Pont De Nemours And Company Hydrogel tissue adhesive having increased degradation time
EP2396035A4 (de) * 2009-02-12 2012-09-12 Human Genome Sciences Inc Verwendung von antagonisten des b-lymphozyten-stimulatorproteins zur förderung von transplantationstoleranz
WO2010100247A1 (en) 2009-03-06 2010-09-10 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Novel therapy for anxiety
CA2754896C (en) * 2009-03-09 2017-11-28 Molecular Express, Inc. Methods and compositions for liposomal formulation of antigens and uses thereof
US8580732B2 (en) * 2009-04-07 2013-11-12 Duke University Peptide therapy for hyperglycemia
EP2416811B1 (de) 2009-04-09 2015-09-09 Actamax Surgical Materials LLC Hydrogel-gewebekleber mit verringerter zerfallszeit
EP2241323A1 (de) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W und Hirnkrebs
US20100330033A1 (en) * 2009-04-16 2010-12-30 Nian Wu Protein-carrier conjugates
AU2010258752B2 (en) 2009-06-09 2015-07-09 Prolong Pharmaceuticals, LLC Hemoglobin compositions
EP2261662B1 (de) * 2009-06-10 2014-01-22 Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften Neuartige synthetische Blockierlösungen
SG10201408480RA (en) 2009-06-25 2015-02-27 Crealta Pharmaceuticals Llc Methods for preventing or predicting infusion reactions or antibody-mediated loss of response, by monitoring serum uric acid levels during pegylated uricase therapy
WO2011002956A1 (en) 2009-07-02 2011-01-06 E. I. Du Pont De Nemours And Company Aldehyde-functionalized polysaccharides
US8580950B2 (en) 2009-07-02 2013-11-12 Actamax Surgical Materials, Llc Aldehyde-functionalized polysaccharides
US8796242B2 (en) 2009-07-02 2014-08-05 Actamax Surgical Materials, Llc Hydrogel tissue adhesive for medical use
EP2448604B1 (de) 2009-07-02 2016-03-23 Actamax Surgical Materials LLC Hydrogel-gewebekleber zum medizinischen gebrauch
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
CN102741422B (zh) 2009-08-24 2016-06-08 阿穆尼克斯运营公司 凝血因子ⅶ组合物及其制备和使用方法
EP2292266A1 (de) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Behandlung von Krebs durch Modulation von Copine III
EP2837392A3 (de) 2009-09-15 2015-05-13 Kaneka Corporation Modifiziertes Erythropoietin, dem ein wasserlösliches langkettiges Molekül hinzugefügt wird
IN2012DN03219A (de) 2009-09-17 2015-10-23 Baxter Healthcare Sa
EP2480573A1 (de) 2009-09-22 2012-08-01 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Behandlung von krebs durch modulation von mex-3
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
WO2011060233A1 (en) 2009-11-11 2011-05-19 The Trustees Of The University Of Pennsylvania Anti-tem1 antibodies and uses thereof
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
BR112012015597A2 (pt) 2009-12-21 2017-01-31 Ambrx Inc peptídeos de somatotropina suínos modificados e seus usos
MX349301B (es) 2009-12-21 2017-07-21 Ambrx Inc Polipéptidos de somatotropina bovina modificados y sus usos.
EP2542578A1 (de) 2010-03-05 2013-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Smoc1, tenascin-c und hirnkrebs
US9815876B2 (en) 2010-03-05 2017-11-14 Omeros Corporation Chimeric inhibitor molecules of complement activation
WO2011131611A1 (en) 2010-04-19 2011-10-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulating xrn1
WO2011136744A1 (en) 2010-04-27 2011-11-03 Agency For Science, Technology And Research Eif4e binding peptides
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
US8828181B2 (en) 2010-04-30 2014-09-09 E I Du Pont De Nemours And Company Temperature switchable adhesives comprising a crystallizable oil
WO2011143274A1 (en) 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptide inhibitors of vla4
US20130089538A1 (en) 2010-06-10 2013-04-11 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh Treating cancer by modulating mammalian sterile 20-like kinase 3
US10040761B2 (en) 2010-06-25 2018-08-07 Nof Corporation Branched hetero polyethylene glycol and intermediate
JP5825507B2 (ja) * 2010-06-25 2015-12-02 日油株式会社 分岐型ヘテロポリエチレングリコール
EP2595624B1 (de) 2010-07-20 2018-01-31 Halozyme, Inc. Verfahren zur linderung bzw. vermeidung der nebenwirkungen im zusammenhang mit der verabreichung eines anti-hyaluronan-mittels
US8409703B2 (en) 2010-07-23 2013-04-02 E I Du Pont De Nemours And Company Temperature switchable adhesive assemblies with temperature non-switchable tack
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
HUE045845T2 (hu) 2010-08-17 2021-12-28 Ambrx Inc Módosított relaxin polipeptidek és felhasználásuk
US20130171159A1 (en) 2010-09-10 2013-07-04 Brian Arthur Hemmings Phosphorylated twist1 and metastasis
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
WO2012065937A1 (en) 2010-11-15 2012-05-24 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Anti-fungal agents
AU2011336470B8 (en) 2010-12-01 2017-09-14 Alderbio Holdings Llc Anti-NGF compositions and use thereof
EP2672958A1 (de) 2011-02-08 2013-12-18 Halozyme, Inc. Zusammensetzung und lipidformulierung eines hyaluronan-abbauenden enzym und seine verwendung zur behandlung von benigner prostatahyperplasie
JP6309273B2 (ja) 2011-03-02 2018-04-11 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 活性化血小板上のｔｌｔ−１に対する凝固因子の標的化
CN103930437A (zh) 2011-03-16 2014-07-16 安姆根有限公司 Nav1.3和Nav1.7的强效及选择性抑制剂
KR102098546B1 (ko) 2011-05-20 2020-04-07 앨더바이오 홀딩스 엘엘씨 필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도
CN103957935B (zh) 2011-05-20 2018-04-03 奥尔德生物控股有限责任公司 抗cgrp或抗cgrp‑r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途
CN108373502B (zh) 2011-05-20 2022-03-22 H.伦德贝克公司 抗cgrp组合物及其用途
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
WO2012168259A1 (en) 2011-06-06 2012-12-13 Novartis Forschungsstiftung, Zweigniederlassung Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
WO2012170969A2 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
EP2720713A2 (de) 2011-06-17 2014-04-23 Halozyme, Inc. Kontinuierliches subkutanes insulininfusionsverfahren mit einem hyaluronanabbauenden enzym
US20130090294A1 (en) 2011-06-28 2013-04-11 Alternative Innovative Technologies Llc Novel methods of use of hsp70 for increased performance or treatment of hsp70 related disorders
CA2840552A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
AU2012278944B2 (en) 2011-07-05 2015-09-17 Bioasis Technologies Inc. p97-antibody conjugates and methods of use
US20130071394A1 (en) 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
US9937241B2 (en) 2011-10-14 2018-04-10 Alternative Innovative Technologies Llc Degradation resistant HSP70 formulations and uses thereof
SG11201401797TA (en) 2011-10-24 2014-09-26 Halozyme Inc Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
EP2776022A1 (de) 2011-11-08 2014-09-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Neue behandlung für neurodegenerative erkrankungen
EP2776838A1 (de) 2011-11-08 2014-09-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Frühe diagnose neurodegenerativer erkrankungen
WO2013101509A2 (en) 2011-12-15 2013-07-04 Alternative Innovative Technologies Llc Hsp70 fusion protein conjugates and uses thereof
PT3130347T (pt) 2011-12-30 2019-12-10 Halozyme Inc Variantes de polipéptidos de ph20, suas formulações e utilizações
EP2800583A1 (de) 2012-01-02 2014-11-12 Novartis AG Cdcp1 und brustkrebs
BR112014017165B1 (pt) 2012-01-12 2023-05-02 Bioverativ Therapeutics Inc Proteína quimérica compreendendo uma proteína de fator viii, composição farmacêutica, e seus usos
JP6383666B2 (ja) 2012-02-15 2018-08-29 バイオベラティブ セラピューティクス インコーポレイテッド 組換え第ｖｉｉｉ因子タンパク質
JP6256882B2 (ja) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
WO2013128003A1 (en) 2012-03-01 2013-09-06 Novo Nordisk A/S N-terminally modified oligopeptides and uses thereof
WO2013144240A1 (en) 2012-03-29 2013-10-03 Friedrich Miescher Institute For Biomedical Research Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
PT2833905T (pt) 2012-04-04 2018-08-06 Halozyme Inc Terapia de combinação com hialuronidase e um taxano dirigido a tumor
MY167814A (en) 2012-04-19 2018-09-26 Opko Biologics Ltd Long-acting oxyntomodulin variants and methods of producing same
US9783610B2 (en) 2012-04-27 2017-10-10 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
AU2013255880B2 (en) 2012-05-01 2017-07-20 Novo Nordisk A/S Pharmaceutical composition
EP2854838B1 (de) 2012-06-04 2018-10-17 OPKO Biologics Ltd. Pegylierte oxm-varianten
AU2013270684B2 (en) 2012-06-08 2018-04-19 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
AU2013270683A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Chimeric clotting factors
JP2015521589A (ja) 2012-06-08 2015-07-30 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． プロコアグラント化合物
GB201210770D0 (en) * 2012-06-18 2012-08-01 Polytherics Ltd Novel conjugation reagents
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
WO2014001482A1 (en) 2012-06-29 2014-01-03 Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research Treating diseases by modulating a specific isoform of mkl1
EP2870242A1 (de) 2012-07-05 2015-05-13 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Neue behandlung für neurodegenerative erkrankungen
SG10201913893XA (en) 2012-07-11 2020-03-30 Bioverativ Therapeutics Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
WO2014014821A1 (en) 2012-07-19 2014-01-23 Redwood Biosciences, Inc. Antibody specific for cd22 and methods of use thereof
JP6433424B2 (ja) 2012-07-31 2018-12-05 バイオアシス テクノロジーズ インコーポレイテッド 脱リン酸化されたリソソーム蓄積症タンパク質およびその使用方法
MX359817B (es) 2012-08-16 2018-10-11 Ipierian Inc Anticuerpos que se enlazan a tau.
ES2907763T3 (es) 2012-08-31 2022-04-26 Sutro Biopharma Inc Aminoácidos modificados que comprenden un grupo azido
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
EP3722320A3 (de) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-komplement-c1s-antikörper und verwendungen davon
JP6543572B2 (ja) 2012-11-02 2019-07-10 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
AU2013341711A1 (en) 2012-11-12 2015-05-21 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
JP2016505528A (ja) 2012-11-16 2016-02-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア タンパク質の化学修飾のためのピクテ−スペングラーライゲーション
US8859705B2 (en) 2012-11-19 2014-10-14 Actamax Surgical Materials Llc Hydrogel tissue adhesive having decreased gelation time and decreased degradation time
CA2891393A1 (en) 2012-11-20 2014-05-30 Opko Biologics Ltd. Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
EP2922870B1 (de) 2012-11-21 2019-08-07 The Governors of the University of Alberta Immunmodulatorische peptide und verfahren zur verwendung davon
JP6426107B2 (ja) 2012-12-20 2018-11-21 アムジエン・インコーポレーテツド Ａｐｊ受容体アゴニストおよびその使用
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
US9272075B2 (en) 2013-02-04 2016-03-01 W.L. Gore & Associates, Inc. Coating for substrate
AU2014211351B2 (en) 2013-02-04 2017-04-13 W. L. Gore & Associates, Inc. Coating for substrate
UY35397A (es) 2013-03-12 2014-10-31 Amgen Inc INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
WO2014160438A1 (en) 2013-03-13 2014-10-02 Bioasis Technologies Inc. Fragments of p97 and uses thereof
WO2014152657A1 (en) 2013-03-14 2014-09-25 Alere San Diego, Inc. 6-acetylmorphine analogs, and methods for their synthesis and use
CN105209497B (zh) 2013-03-15 2021-09-07 诺和诺德股份有限公司 能够特异性结合组织因子途径抑制物上的两个表位的抗体
CN105189606B (zh) 2013-03-27 2017-06-09 日油株式会社 具有一个氨基的聚乙二醇的纯化方法
EP2986306A4 (de) 2013-04-18 2016-12-07 Armo Biosciences Inc Verfahren zur verwendung von interleukin-10 zur behandlung von erkrankungen und leiden
AU2014257131B9 (en) 2013-04-23 2019-12-05 Nizyme, Inc. Methods and compositions for treating diseases
PL3007726T3 (pl) 2013-06-10 2021-01-11 Ipierian, Inc. Metody leczenia tauopatii
CA2914837A1 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
MX2016000220A (es) 2013-07-03 2016-08-18 Alder Biopharmaceuticals Inc Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
ES2658039T3 (es) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
EP3027659B1 (de) 2013-07-29 2020-12-09 Actamax Surgical Materials LLC Gewebeklebstoff mit niedriger schwellung und dichtungsmittelzusammensetzungen
US20160178610A1 (en) 2013-08-07 2016-06-23 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment Friedreich's ataxia
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
EP3038642A4 (de) 2013-08-30 2017-01-18 Armo Biosciences, Inc. Verfahren zur verwendung von interleukin-10 zur behandlung von erkrankungen und leiden
EP3760639A1 (de) 2013-09-08 2021-01-06 Kodiak Sciences Inc. Zwitterionische polymerkonjugate
EP3048899B1 (de) 2013-09-25 2021-09-08 Bioverativ Therapeutics Inc. Verfahren zur virusinaktivierung auf einer säule
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EP3065769A4 (de) 2013-11-08 2017-05-31 Biogen MA Inc. Prokoagulatorische fusionsverbindung
JP6660297B2 (ja) 2013-11-11 2020-03-11 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を処置するためのインターロイキン−１０の使用方法
WO2015081282A1 (en) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
JP6629201B2 (ja) 2013-11-27 2020-01-15 アイピエリアン，インコーポレイティド タウオパチーの処置方法
RS63583B1 (sr) 2014-01-10 2022-10-31 Bioverativ Therapeutics Inc Himerni proteini faktora viii i njihova upotreba
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
JP6803236B2 (ja) 2014-06-10 2020-12-23 アムジェン インコーポレイテッド アペリンポリペプチド
WO2015189816A1 (en) 2014-06-13 2015-12-17 Friedrich Miescher Institute For Biomedical Research New treatment against influenza virus
US10308935B2 (en) 2014-06-23 2019-06-04 Friedrich Miescher Institute For Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small RNAS
EP3186281B1 (de) 2014-08-28 2019-04-10 Halozyme, Inc. Kombinationstherapie mit einer hyaluronanabbauendem enzym und einem immun-checkpoint-hemmer
WO2016046768A1 (en) 2014-09-24 2016-03-31 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
AP2017009826A0 (en) 2014-09-26 2017-03-31 Bayer Pharma AG Stabilized adrenomedullin derivatives and use thereof
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
NZ730563A (en) 2014-10-14 2019-05-31 Halozyme Inc Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
JP6675394B2 (ja) 2014-10-22 2020-04-01 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害の治療のためにインターロイキン−１０を使用する方法
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
KR102569907B1 (ko) 2014-10-23 2023-08-24 엔지엠 바이오파마슈티컬스, 아이엔씨. 펩티드 변이체를 포함하는 약제학적 조성물 및 그의 사용 방법
EA036697B1 (ru) 2014-10-24 2020-12-09 Бристол-Майерс Сквибб Компани Модифицированные полипептиды fgf-21 и их применение
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
KR20230079520A (ko) 2014-11-06 2023-06-07 파마에센시아 코퍼레이션 Peg화된 인터페론의 투약 요법
ES2748692T3 (es) 2014-11-19 2020-03-17 Nzp Uk Ltd Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la producción de moduladores FXR de esteroides
EP3221334B1 (de) 2014-11-19 2020-02-19 Nzp Uk Limited 6.alpha-alkyl-6,7-dionsteroide als zwischenprodukte zur herstellung von steroiden fxr-modulatoren
CN107108687B (zh) 2014-11-19 2019-10-29 Nzp英国有限公司 作为制备类固醇FXR调节剂的中间体的5β-6-烷基-7-羟基-3-酮类固醇
EP3786182A1 (de) 2014-11-19 2021-03-03 Axon Neuroscience SE Humanisierte tau-antikörper bei alzheimer-krankheit
DK3221331T3 (da) 2014-11-19 2019-12-02 Nzp Uk Ltd 6-alkyl-7-hydroxy-4-en-3-on-steroider som mellemprodukter til fremstilling af steroide fxr-modulatorer
EP3835319A1 (de) 2014-12-19 2021-06-16 Alder Biopharmaceuticals, Inc. Humanisierte anti-acth-antikörper und verwendungen davon
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP4014985A1 (de) 2015-05-01 2022-06-22 Allysta Pharmaceuticals, Inc. Adiponectin-peptidomimetika zur behandlung von augenerkrankungen
AU2016268403A1 (en) 2015-05-28 2017-12-07 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
EP3302571B1 (de) 2015-05-29 2020-11-18 OPKO Biologics Ltd. Pegylierte oxyntomodulin-varianten
CA2986774A1 (en) 2015-05-29 2016-12-08 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
ES2902467T3 (es) 2015-06-15 2022-03-28 Univ Leland Stanford Junior TIMP2 para su uso en el tratamiento de afecciones asociadas al envejecimiento
CN108289851B (zh) 2015-06-19 2021-06-01 Opko生物科学有限公司 长效凝固因子及其产生方法
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
CA2994971A1 (en) 2015-08-12 2017-02-16 Cell Machines, Inc. Methods and compositions related to long half-life coagulation complexes
EP3341012A4 (de) 2015-08-25 2019-03-20 Armo Biosciences, Inc. Verfahren zur verwendung von interleukin-10 zur behandlung von erkrankungen und leiden
EP3798234A1 (de) 2015-09-02 2021-03-31 Immutep S.A.S. Agonistische anti-lag-3 antikörper
WO2017059338A1 (en) * 2015-10-02 2017-04-06 Cornell University Enzyme-responsive peptide nanofiber compositions and uses thereof
US20180348224A1 (en) 2015-10-28 2018-12-06 Friedrich Miescher Institute For Biomedical Resear Ch Tenascin-w and biliary tract cancers
EP3377090B1 (de) 2015-11-09 2021-04-07 NGM Biopharmaceuticals, Inc. Verfahren zur behandlung von gallensäurebedingten erkrankungen
RS63070B1 (sr) 2015-11-09 2022-04-29 Univ Colorado Regents Kompozicije i postupci za upotrebu u lečenju homocistinurije
KR20180104106A (ko) 2016-01-27 2018-09-19 서트로 바이오파마, 인크. anti-CD74 항체 접합체, anti-CD74 항체 접합체를 포함하는 조성물 및 anti-CD74 항체 접합체의 이용 방법
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
BR112018070357A2 (pt) 2016-04-04 2019-01-29 Bioverativ Usa Inc anticorpos anticomplemento contra o fator bb e seus usos
US10202435B2 (en) 2016-04-15 2019-02-12 Alder Biopharmaceuticals, Inc. Anti-PACAP antibodies and uses thereof
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
EP3458439B1 (de) 2016-05-18 2021-12-08 Alere San Diego, Inc. 2-ethyliden-1,5-dimethyl-3,3-diphenylpyrrolidin-analoga sowie methoden zu deren synthese und verwendung
WO2017212494A1 (en) 2016-06-09 2017-12-14 Opko Biologics Ltd. Long-acting oxyntomodulin formulation and methods of producing and administering same
CN109891237B (zh) 2016-10-24 2022-08-23 诺和诺德股份有限公司 胰岛素制剂的生物测定法
NZ752394A (en) 2016-11-14 2021-07-30 Hangzhou Dac Biotech Co Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
EP3562840A1 (de) 2016-12-16 2019-11-06 Biogen MA Inc. Stabilisierter proteolytisch aktivierter wachstumsdifferenzierungsfaktor 11
CA3052639A1 (en) 2017-02-08 2018-08-16 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
JP6935059B2 (ja) 2017-03-30 2021-09-15 日油株式会社 カルボキシル基を一つ有するポリエチレングリコールの精製方法
JP7146897B2 (ja) 2017-04-17 2022-10-04 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト ホモシスチン尿症の治療のための酵素補充療法の最適化
US20200115324A1 (en) 2017-06-11 2020-04-16 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
CN111107870A (zh) 2017-06-22 2020-05-05 催化剂生物科学公司 经修饰的膜型丝氨酸蛋白酶1（mtsp-1）多肽及其使用方法
WO2019023316A1 (en) 2017-07-26 2019-01-31 Sutro Biopharma, Inc. METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA
WO2019030692A1 (en) 2017-08-10 2019-02-14 Friedrich Miescher Institute For Biomedical Research HDAC6 AND AGGREGATION OF PROTEINS
US20200353076A1 (en) 2017-09-18 2020-11-12 Sutro Biopharma, Inc. Anti-folate receptor alpha antibody conjugates and their uses
WO2019094268A1 (en) 2017-11-10 2019-05-16 Armo Biosciences, Inc. Compositions and methods of use of interleukin-10 in combination with immune checkpoint pathway inhibitors
CN111094462A (zh) 2017-12-26 2020-05-01 贝克顿·迪金森公司 深紫外线可激发的水溶剂化聚合物染料
EA202092316A1 (ru) 2018-03-28 2021-05-25 Бристол-Маерс Сквибб Компани Слитые белки интерлейкина-2/альфа-рецептора интерлейкина-2 и способы применения
JP2021519841A (ja) 2018-03-30 2021-08-12 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ ペンダントクロモフォアを有する水溶性ポリマー色素
WO2019211842A1 (en) 2018-04-30 2019-11-07 Opko Biologics Ltd. Long-acting human growth hormone-antagonists and methods of producing the same
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
CN112533629A (zh) 2018-06-19 2021-03-19 阿尔莫生物科技股份有限公司 结合使用il-10药剂与嵌合抗原受体细胞疗法的组合物和方法
JP2021529763A (ja) 2018-07-03 2021-11-04 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｆｇｆ−２１製剤
EP3813867A1 (de) 2018-07-22 2021-05-05 Bioasis Technologies Inc. Behandlung von lymphatischen metastasen
FI3849614T3 (fi) 2018-09-11 2024-02-08 Ambrx Inc Interleukiini-2-polypeptidikonjugaatteja ja niiden käyttöjä
US20220047716A1 (en) 2018-09-17 2022-02-17 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
JP2022512746A (ja) 2018-10-19 2022-02-07 アンブルックス，インコーポレイテッド インターロイキン－１０ポリペプチド複合体、その二量体、およびそれらの使用
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
KR20210110848A (ko) 2018-12-28 2021-09-09 카탈리스트 바이오사이언시즈, 인코포레이티드 변형된 유로키나제 유형 플라스미노겐 활성제 폴리펩타이드 및 사용 방법
CN113710692A (zh) 2019-02-11 2021-11-26 Opko生物科学有限公司 长效glp-2类似物
BR112021015832A2 (pt) 2019-02-12 2022-01-18 Ambrx Inc Composições que contêm conjugados de anticorpo-agonista de tlr, métodos e usos dos mesmos
EP3962951A1 (de) 2019-05-03 2022-03-09 Sutro Biopharma, Inc. Anti-bcma-antikörper-konjugate
CN114269749A (zh) 2019-06-10 2022-04-01 苏特罗生物制药公司 5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物
JP2022536800A (ja) 2019-06-17 2022-08-18 ストロ バイオファーマ インコーポレーテッド Ｔｏｌｌ様受容体（ｔｌｒ）７／８アゴニストとしての１－（４－（アミノメチル）ベンジル）－２－ブチル－２ｈ－ピラゾロ［３，４－ｃ］キノリン－４－アミン誘導体および関連化合物、ならびにがん療法および診断に使用するためのその抗体薬物コンジュゲート
JP2022537369A (ja) 2019-06-18 2022-08-25 バイエル アクチェンゲゼルシャフト 長期安定化のためのアドレノメデュリン－類似体およびその使用
WO2021038296A2 (en) 2019-08-27 2021-03-04 Tonix Pharma Holdings Limited Modified tff2 polypeptides
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
MX2022008336A (es) 2020-01-08 2022-08-08 Bristol Myers Squibb Co Formulaciones de conjugados del factor de crecimiento de fibroblastos 21 (fgf-21).
EP4114852A1 (de) 2020-03-03 2023-01-11 Sutro Biopharma, Inc. Antikörper mit stellenspezifischen glutamin-tags, verfahren zu ihrer herstellung und verfahren zu ihrer verwendung
AU2021233909A1 (en) 2020-03-11 2022-09-29 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
AU2020202454A1 (en) 2020-04-06 2021-10-21 H. Lundbeck A/S Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies
BR112022022045A2 (pt) 2020-04-30 2023-01-10 Sairopa B V Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao cd103 humano, um ou mais ácidos nucleicos, sistema de expressão, célula hospedeira, composição, métodos de produção de um anticorpo ou fragmento de ligação ao antígeno, para detectar a presença de cd103 em uma amostra biológica, para tratar ou prevenir uma condição mediada por sinalização de cd103 em um indivíduo em necessidade, para inibir a sinalização de cd103 em uma célula, para inibir a ligação de cd103 à e-caderina presente em uma célula, para retirar as células que expressam cd103 em um indivíduo, para tratar ou prevenir uma doença e agente de imageamento
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
EP4192495A1 (de) 2020-08-07 2023-06-14 Bristol-Myers Squibb Company Fgf21 in kombination mit ccr2/5-antagonisten zur behandlung von fibrose
CA3128035A1 (en) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Combination therapies for delivery across the blood brain barrier
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
WO2022103983A2 (en) 2020-11-11 2022-05-19 Sutro Biopharma, Inc. Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
US20240123031A1 (en) 2020-11-25 2024-04-18 Bristol-Myers Squibb Company Methods of treating liver diseases
WO2022212899A1 (en) 2021-04-03 2022-10-06 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof
US11931420B2 (en) 2021-04-30 2024-03-19 Celgene Corporation Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)
IL310248A (en) 2021-08-20 2024-03-01 Bayer Ag A process for the preparation of polyethylene glycol-modified adrenomedullin, its intermediates and their use
WO2023026245A1 (en) 2021-08-27 2023-03-02 H. Lundbeck A/S Treatment of cluster headache using anti-cgrp antibodies
EP4155349A1 (de) 2021-09-24 2023-03-29 Becton, Dickinson and Company Wasserlösliche gelbe grünabsorbierende farbstoffe
WO2024006272A1 (en) 2022-06-27 2024-01-04 Sutro Biopharma, Inc. β-GLUCURONIDE LINKER-PAYLOADS, PROTEIN CONJUGATES THEREOF, AND METHODS THEREOF
US20240058465A1 (en) 2022-06-30 2024-02-22 Sutro Biopharma, Inc. Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates
WO2024007016A2 (en) 2022-07-01 2024-01-04 Beckman Coulter, Inc. Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
WO2024015229A1 (en) 2022-07-15 2024-01-18 Sutro Biopharma, Inc. Protease/enzyme cleavable linker-payloads and protein conjugates
WO2024044780A1 (en) 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
WO2024044327A1 (en) 2022-08-26 2024-02-29 Beckman Coulter, Inc. Dhnt monomers and polymer dyes with modified photophysical properties

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
IL47468A (en) * 1975-06-12 1979-05-31 Rehovot Res Prod Process for the cross-linking of proteins using water soluble cross-linking agents
EP0000938B1 (de) * 1977-08-22 1984-10-17 National Research Development Corporation Makromolekulare kovalente Konjugate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4680338A (en) * 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4889916A (en) * 1985-11-19 1989-12-26 The Johns Hopkins University Protein label and drug delivery system
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US4846548A (en) * 1987-05-06 1989-07-11 St&E, Inc. Fiber optic which is an inherent chemical sensor
US5229490A (en) * 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
JP2958019B2 (ja) * 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
US5214131A (en) * 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5091176A (en) * 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
HUT64022A (en) * 1989-04-19 1993-11-29 Enzon Inc Process for producing active polyalkileneoxide carbonates for the modification of polypeptides
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
GB8918589D0 (en) * 1989-08-15 1989-09-27 Graham Neil B Polymeric compositions
US5091542A (en) * 1990-03-09 1992-02-25 Hybritech Incorporated Tris-maleimido compounds as intermediates in trifunctional antibody synthesis
US5219564A (en) * 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
NZ244778A (en) * 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
WO1993024476A1 (en) * 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5514379A (en) * 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
US5321095A (en) * 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles

Also Published As

Publication number Publication date
DE69427045T2 (de) 2001-10-25
EP0788515B1 (de) 2001-04-04
DE69434046T2 (de) 2005-10-06
JP3626494B2 (ja) 2005-03-09
EP0788515A4 (de) 1998-07-01
CA2174325A1 (en) 1995-05-04
EP1055685A1 (de) 2000-11-29
DE69427045D1 (de) 2001-05-10
EP1055685B1 (de) 2004-09-29
DK1055685T3 (da) 2005-01-03
US5643575A (en) 1997-07-01
DK0788515T3 (da) 2001-07-16
AU8090294A (en) 1995-05-22
WO1995011924A1 (en) 1995-05-04
CA2174325C (en) 2009-05-26
EP0788515A1 (de) 1997-08-13
JPH09504299A (ja) 1997-04-28

Similar Documents

Publication Publication Date Title
DK0788515T3 (da) Ikke-antigene forgrenede polymerkonjugater
BR9406669A (pt) Composiçao polimerica
DE69400665D1 (de) Gummiartiges Polymer
DK1039922T3 (da) Forbedrede interferonpolymerkonjugater
BR9610057A (pt) Polímeros ramificados
DK130991D0 (da) Polymere konjugater
DK0675727T3 (da) Glycolipidenzympolymerkonjugater
DK0791016T3 (da) Polymersyntese
DE69632633D1 (de) Polymerzusammensetzung
DE69607027T2 (de) Polymermassen
DE69608496T2 (de) Polymerfilme
DK0637603T3 (da) Polymerfilm
ATA903396A (de) Zwei-komponenten-polymerzusammensetzung
DE59409992D1 (de) Polymer-Legierung
DE69617439T2 (de) Härtbare polymerzusammensetzung
DE69627451D1 (de) Polymerfilme
DE69314661D1 (de) Polymermischungen
DE69624817D1 (de) Carboxylgruppen enthaltende polymerzusammensetzung
DE69407073T2 (de) Hochtransparente zähe Polymermischungen
DE69419449D1 (de) Thermoplastische Polymerzusammensetzung
FI932578A0 (fi) Foerfarande foer framstaellning av elledande polymer
BR9501238A (pt) Substrato polimérico transparente
DE69604682T2 (de) Polymermischungen
FI941971A0 (fi) Polymeeriseoksia
DE59711493D1 (de) Polymerzusammensetzung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition